GlobeNewsWire
06 Feb 2026, 12:55 UTC · 32w ago
Verdict
Headline takes no side. We score CMND +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Polyrizon (PLRZ) and Clearmind Medicine (CMND) have entered into a development agreement to create an intranasal formulation of the drug candidate MEAI.
More positive than 77% of claims this week
The collaboration focuses on treating addiction-related and other central-nervous-system (CNS) conditions using a non-hallucinogenic neuroplastogen.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 50% of claims this week
Polyrizon will utilize its proprietary Trap and Target (T&T) technology to enable more targeted and efficient delivery of Clearmind's API.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company is advancing its drug candidate MEAI through a new collaboration to improve delivery and clinical development.
More positive than 73% of ticker scores this week
The company entered into a strategic development agreement to leverage its proprietary technology for a drug candidate.
More positive than 76% of relationship scores this week
[mutual] Polyrizon and Clearmind entered into a development agreement to create an intranasal formulation of Clearmind's drug candidate MEAI.
More positive than 35% of relationship scores this week
[a_to_b] Polyrizon provides its proprietary intranasal delivery platform to support Clearmind's clinical development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
7h ago
Accesswire
7h ago
−94.4%
Price is moving against the score
$0.8098 vs $14.50 close before publication (Feb 5) · not market-adjusted
CMND chart →
